QURE
Price
$23.11
Change
+$0.42 (+1.85%)
Updated
Oct 22 closing price
Capitalization
1.6B
17 days until earnings call
Intraday BUY SELL Signals
TCRX
Price
$0.22
Change
-$0.00 (-0.00%)
Updated
Oct 22 closing price
Capitalization
14.65M
19 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

QURE vs TCRX

QURE vs TCRX Comparison Chart in %
View a ticker or compare two or three
VS
QURE vs. TCRX commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is QURE is a Hold and TCRX is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for QURE with price predictions
Oct 22, 2026

QURE in upward trend: price may jump up because it broke its lower Bollinger Band on September 29, 2026

QURE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 27 of 33 cases where QURE's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where QURE's RSI Oscillator exited the oversold zone, 26 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.

The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on QURE as a result. In 67 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.

The Moving Average Convergence Divergence (MACD) for QURE just turned positive on October 16, 2026. Looking at past instances where QURE's MACD turned positive, the stock continued to rise in 33 of 41 cases over the following month. The odds of a continued upward trend are 80%.

Following a +4.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where QURE advanced for three days, in 206 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

QURE moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for QURE crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where QURE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for QURE entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.947) is normal, around the industry mean (2.973). P/E Ratio (-5.692) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (142.857) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. QURE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QURE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for TCRX with price predictions
Oct 22, 2026

TCRX in -12.16% downward trend, falling for three consecutive days on October 19, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where TCRX declined for three days, in 291 of 317 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TCRX as a result. In 77 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

The Aroon Indicator for TCRX entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TCRX's RSI Oscillator exited the oversold zone, 32 of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 58 cases where TCRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.

The Moving Average Convergence Divergence (MACD) for TCRX just turned positive on September 22, 2026. Looking at past instances where TCRX's MACD turned positive, the stock continued to rise in 41 of 49 cases over the following month. The odds of a continued upward trend are 84%.

Following a +1.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where TCRX advanced for three days, in 189 of 236 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

TCRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.212) is normal, around the industry mean (2.973). P/E Ratio (-0.240) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (6.046) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. TCRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TCRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
QURE: Fundamental Ratings
QURE
OUTLOOK RATING
1..100
2
VALUATION
overvalued / fair valued / undervalued
1..100
41
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
65
P/E GROWTH RATING
1..100
12
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
QURETCRX
RSI
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
84%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
88%
MACD
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
89%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 21 days ago
80%
Declines
ODDS (%)
Bearish Trend 9 days ago
86%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
82%
Aroon
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
89%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (QURE: $23.11 vs. TCRX: $0.22)
Brand notoriety: QURE and TCRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: QURE: 73% vs. TCRX: 34%
Market capitalization -- QURE: $1.6B vs. TCRX: $14.65M
QURE [@Biotechnology] is valued at $1.6B. TCRX’s [@Biotechnology] market capitalization is $14.65M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

QURE’s FA Score shows that 1 FA rating(s) are green while TCRX’s FA Score has 1 green FA rating(s).

  • QURE’s FA Score: 1 green, 4 red.
  • TCRX’s FA Score: 1 green, 4 red.
According to our system of comparison, QURE is a better buy in the long-term than TCRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

QURE’s TA Score shows that 5 TA indicator(s) are bullish while TCRX’s TA Score has 5 bullish TA indicator(s).

  • QURE’s TA Score: 5 bullish, 5 bearish.
  • TCRX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, TCRX is a better buy in the short-term than QURE.

Price Growth

QURE (@Biotechnology) experienced а +2.62% price change this week, while TCRX (@Biotechnology) price change was -9.65% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.

Reported Earning Dates

QURE is expected to report earnings on Nov 09, 2026.

TCRX is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-1.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
QURE
Daily Signal:
Gain/Loss:
TCRX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

QURE and

Correlation & Price change

A.I.dvisor indicates that over the last year, QURE has been loosely correlated with CNTN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if QURE jumps, then CNTN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QURE
1D Price
Change %
QURE100%
+1.85%
CNTN - QURE
49%
Loosely correlated
-3.63%
AXON - QURE
42%
Loosely correlated
+2.98%
MLTX - QURE
37%
Loosely correlated
+15.87%
SNGX - QURE
36%
Loosely correlated
+0.30%
STOK - QURE
34%
Loosely correlated
+0.08%
More

TCRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, TCRX has been loosely correlated with CELC. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if TCRX jumps, then CELC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TCRX
1D Price
Change %
TCRX100%
-3.48%
CELC - TCRX
36%
Loosely correlated
+6.51%
QURE - TCRX
35%
Loosely correlated
+1.85%
MGX - TCRX
33%
Loosely correlated
-1.52%
AGIO - TCRX
33%
Poorly correlated
+0.03%
MLTX - TCRX
32%
Poorly correlated
+15.87%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ICUI168.337.49
+4.66%
ICU Medical
ENGS4.210.12
+2.93%
Energys Group Limited
VOD16.120.27
+1.70%
Vodafone Group Plc
LICN0.85-0.01
-0.81%
Lichen International Limited
MCS28.30-0.53
-1.84%
Marcus Corp (The)